[The effects of a trehalose-based drug used after laser keratorefractive surgeries]. / Rezul'taty primeneniya preparata na osnove Tregalozy posle lazernykh keratorefraktsionnykh operatsii.

PURPOSE: To analyze the effectiveness of artificial tear drops Thealoz (trehalose 3%) in the correction of dry eye syndrome (DES) after ReLEx SMILE and FEMTO LASIK keratorefractive surgeries. MATERIAL AND METHODS: The study included 20 patients (40 eyes) who underwent a keratorefractive surgery and were prescribed instillations of Thealoz artificial tear drops for the correction of dry eye syndrome. Patients were divided into 2 group: the 1st group consisted of 10 patients who underwent ReLEx SMILE surgery, the 2nd group - 10 patients after FEMTO LASIK. The effectiveness of the treatment was evaluated at 1 and 3 months after the surgery using Ocular Surface Disease Index (OSDI), changes in the anterior corneal epithelium (Oxford scale), and tear break-up time (Norn's test). RESULTS: It was found that the use of artificial tear drops Thealoz regardless of the type of keratorefractive surgery helps reduce discomfort based on the OSDI questionnaire from 10.90±4.55 to 10.20±4.07 and 8.89±3.26 points by 1 and 3 months of the follow-up, respectively (p≤0.05). The degree of epitheliopathy according to the Oxford scale decreases from 0.73±0.75 to 0.25±0.43 points 3 months after the surgery (p≤0.05), which is accompanied by a significant increase in tear break-up time (Norn's test) from 11.18±1.19 to 12.43±1.03 and 12.45±1.03 seconds 1 and 3 months after treatment, respectively (p≤0,05). CONCLUSION: Complex evaluation of the ocular surface has proved that artificial tear drops Thealoz is effective in reducing DES manifestations after keratorefractive surgery. The results clearly demonstrate that the drug helps increase stability of the tear break-up time, as well as contributes to the decrease in epitheliopathy and subjective discomfort sensations, giving grounds to widen its use in clinical practice.

[Artificial tear drops Thealoz in the correction of dry eye syndrome after keratorefractive surgery]. / Primenenie preparata Tealoz v korrektsii sindroma sukhogo glaza posle keratorefraktsionnykh operatsii.

PURPOSE: To analyze the effectiveness of artificial tear drops Thealoz (trehalose 3%) in the correction of dry eye syndrome (DES) after keratorefractive surgery based on instrumental monitoring of the condition of eye surface. MATERIAL AND METHODS: The study included 20 patients (40 eyes) who underwent a keratorefractive surgery and were prescribed instillations of Thealoz artificial tear drops for the correction of dry eye syndrome. Patients were divided into 2 groups: the 1st group consisted of 10 patients who underwent ReLEx SMILE surgery, the 2nd group - 10 patients after FEMTO LASIK. The effectiveness of the treatment was evaluated at 1 and 3 months after the surgery using conventional instrumental monitoring: tear break-up time (Norn's test), tear film osmolarity test and OCT-meniscometry. RESULTS: Regardless of the type of surgery, tear film break-up time has significantly increased from 11.16±0.38 sec to 12.95±0.24 (p≤0.05) and 13.85±0.03 (p≤0.05) by months 1 and 3, respectively; it correlated with progressive decrease of tear film osmolarity from 317.29±1.39 to 308.00±0.79 mOsm/L (p≤0.05) at one month, and by the 3rd month - to 301.75±0.27 mOsm/L (p≤0.05). An improvement in OCT-meniscometry parameters was also observed in the form of a significant increase of the height and depth after 1 and 3 months. CONCLUSION: The use of artificial tear drops Thealoz contributes to the reduction of DES manifestations after keratorefractive surgery: increased stability of the tear film, restoration of the tear meniscus parameters and tear film osmolarity. The use of trehalose ophthalmic solution is advisable in patients after keratorefractive surgery.